/
/
GliMR’s first year has ended

GliMR’s first year has ended

Letter from the Chair
Share:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
year1_banner

Letter from the Chair

The first Grant Period of our COST Action Glioma MR Imaging 2.0 has drawn to a close. We can look back at a great start. Despite the Corona pandemic, which did indeed led to a very different end to our first Grant Period than was intended, many goals were achieved. Additionally, the website, newsletter, and social media accounts were launched – online tools that are more important than ever in creating and fostering our international community.

Planning of the coming grant period, which runs from May 2020 to April 2021, in the current situation is all but easy. However, we are working on ensuring that, also in these trying times, GliMR will succeed in bringing glioma researchers across Europe together.

In the meantime, we hope that all of you keep on participating in GliMR. Keep on working on those review papers, keep engaging with us via social media, and if you have any suggestions of (online) events to be organised do not hesitate to get in touch with your working group / WG5 / the leadership to see what can be arranged.

Keep safe and carry on with glioma research! 

Best wishes,
Esther Warnert

Recent News

Do you want to use machine learning to improve brain tumor imaging? Your challenge You will explore whether MRI diagnostics in brain tumor (glioma) patients can be performed without using the commonly used contrast agent gadolinium but instead using...

Abstract Submission PPT incl QR Code

Submit your abstract for ESMRMB 2021! The deadline is extended to June 8th, 2021. More information can be found on the ESMRMB website. Make sure you use the proper COST and GliMR acknowledgements. This is one of the requirements...

Congratulations to our Researcher of the Month: Patrick Tang Don’t forget to nominate one of our colleagues for researcher of the month! Patrick Tang Patrick is a MSc student Technical Medicine at the Erasmus Medical Center in the Netherlands....